vs

Side-by-side financial comparison of Digi Power X Inc. (DGXX) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Digi Power X Inc. is the larger business by last-quarter revenue ($24.2M vs $19.6M, roughly 1.2× STANDARD BIOTOOLS INC.). Digi Power X Inc. runs the higher net margin — 17.9% vs -177.4%, a 195.3% gap on every dollar of revenue.

X Development LLC, doing business as X, is an American semi-secret research and development facility and organization founded by Google in January 2010. X has its headquarters about a mile and a half from Google's corporate headquarters, the Googleplex, in Mountain View, California.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

DGXX vs LAB — Head-to-Head

Bigger by revenue
DGXX
DGXX
1.2× larger
DGXX
$24.2M
$19.6M
LAB
Higher net margin
DGXX
DGXX
195.3% more per $
DGXX
17.9%
-177.4%
LAB

Income Statement — Q4 FY2022 vs Q3 FY2025

Metric
DGXX
DGXX
LAB
LAB
Revenue
$24.2M
$19.6M
Net Profit
$4.3M
$-34.7M
Gross Margin
48.5%
Operating Margin
-116.7%
-168.5%
Net Margin
17.9%
-177.4%
Revenue YoY
-11.5%
Net Profit YoY
-28.8%
EPS (diluted)
$0.16
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DGXX
DGXX
LAB
LAB
Q3 25
$19.6M
Q2 25
$21.8M
Q1 25
$40.8M
Q3 24
$22.1M
Q2 24
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
DGXX
DGXX
LAB
LAB
Q3 25
$-34.7M
Q2 25
$-33.5M
Q1 25
$-26.0M
Q3 24
$-26.9M
Q2 24
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
DGXX
DGXX
LAB
LAB
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
DGXX
DGXX
LAB
LAB
Q3 25
-168.5%
Q2 25
-118.1%
Q1 25
-80.8%
Q3 24
-120.9%
Q2 24
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
DGXX
DGXX
LAB
LAB
Q3 25
-177.4%
Q2 25
-153.7%
Q1 25
-63.8%
Q3 24
-122.0%
Q2 24
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
DGXX
DGXX
LAB
LAB
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DGXX
DGXX
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$1.9M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$47.2M
$399.7M
Total Assets
$52.6M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DGXX
DGXX
LAB
LAB
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
DGXX
DGXX
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
DGXX
DGXX
LAB
LAB
Q3 25
$399.7M
Q2 25
$424.5M
Q1 25
$454.6M
Q3 24
$489.3M
Q2 24
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
DGXX
DGXX
LAB
LAB
Q3 25
$539.6M
Q2 25
$557.0M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
DGXX
DGXX
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DGXX
DGXX
LAB
LAB
Operating Cash FlowLast quarter
$-15.5M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
-3.58×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DGXX
DGXX
LAB
LAB
Q3 25
$-22.2M
Q2 25
$-20.7M
Q1 25
$-30.3M
Q3 24
$-27.9M
Q2 24
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
DGXX
DGXX
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
DGXX
DGXX
LAB
LAB
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
DGXX
DGXX
LAB
LAB
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DGXX
DGXX

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons